In prep for COVID-19 vaccine reactions?
Unfortunately, it may be too late for ivermectin to do much good for that patient.
Four out of 10 COVID-19 “cases” have no symptoms. I’m uncomfortable calling you a “case” of illness if you never have any signs or symptoms of being sick. The article authors are concerned that asymptomatic “cases” can and will spread infection and make others sick.
COVID-19, the disease caused by SARS-CoV-2, was first reported in December 2019.1 Globally, as of January 28, 2021, there have been 100 455 529 confirmed cases, including 2 166 440 deaths.2 The disease course of COVID-19 ranges from asymptomatic to mild respiratory infections to pneumonia and even to acute respiratory distress syndrome.3 Patients with no symptoms at screening point were defined as having asymptomatic infections, which included infected people who have not yet developed symptoms but go on to develop symptoms later (presymptomatic infections), and those who are infected but never develop any symptoms (true asymptomatic or covert infections).4,5 Owing to the absence of symptoms, these patients would not seek medical care and could not be detected by temperature screening. Presymptomatic transmission will also make temperature screening less effective.6 Only extensive testing and close contact tracing could lead to identification of more asymptomatic infections.7
Unlike SARS [sudden adult respiratory syndrome], which had little known transmission from asymptomatic patients, evidence showed that asymptomatic patients were a potential source of transmission of COVID-19.3,6 A previous study8 showed that the upper respiratory viral loads in asymptomatic patients were comparable to those in symptomatic patients. Meanwhile, the highest viral load in throat swabs at the time of symptom onset indicated that infectiousness peaked on or before symptom onset.9 Moreover, studies showed that asymptomatic infections might have contributed to transmission among households, nursing facilities, and clusters.10–13 As the pandemic has been contained in many countries and regions, travel restrictions have been lifted and public places have reopened. Asymptomatic infections should be considered a source of COVID-19 infections that play an important role in the spread of the virus within community as public life gradually returns to normal. The management of asymptomatic carriers was essential for preventing cluster outbreaks and transmission within a community.
You WILL NOT hear this from the mainstream media:
LOL. “Do as I say, not as I do.”
Did they feel safe questioning the official narrative since both CEOs are retiring soon?
Are they declining because of lack of efficacy or fear of side effects, or both? Sometimes it’s good to know you are not alone.
Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.
I’d have more faith in this study if it weren’t funded by the maker of remdesivir, Gilead Sciences.
Participants who received a booster at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19 than participants who did not receive a booster.
This study was done in Israel in August and September 2021, when the delta variant was rampant.
Multiple studies published this week have suggested Omicron is far less dangerous than Delta, with a UK Health Security Agency report from Thursday saying the mutant strain is 70 per cent less likely to cause hospitalization than Delta, and 45 per cent less likely to require an emergency room visit.
Dr Robert Malone predicts that the Omicron variant will help end the pandemic because so many people will develop immunity by being mildly infected.
Steve Parker, M.D.